NYE METODER: molecules with a published decision record
232 molecules on this site carry at least one NYE METODER decision. Each page compares that decision with every other agency that assessed the same molecule.
| Molecule | Decisions | Agencies | Class |
|---|---|---|---|
| pembrolizumab | 371 | 15 | Antineoplastics |
| nivolumab | 264 | 15 | Antineoplastics |
| adalimumab | 133 | 11 | Immunosuppressants |
| atezolizumab | 120 | 14 | Antineoplastics |
| dupilumab | 116 | 15 | Other dermatologicals |
| daratumumab | 115 | 15 | Antineoplastics |
| olaparib | 114 | 15 | Antineoplastics |
| durvalumab | 108 | 15 | Antineoplastics |
| ibrutinib | 108 | 15 | Antineoplastics |
| rituximab | 94 | 9 | Antineoplastics |
| upadacitinib | 93 | 16 | Immunosuppressants |
| ivacaftor | 79 | 12 | Other respiratory |
| bevacizumab | 77 | 10 | Antineoplastics |
| budesonide | 76 | 12 | Antidiarrheals / intestinal anti-inflammatories |
| tocilizumab | 76 | 12 | Immunosuppressants |
| ustekinumab | 71 | 11 | Immunosuppressants |
| lenalidomide | 68 | 13 | Immunosuppressants |
| aflibercept | 67 | 11 | Antineoplastics |
| denosumab | 67 | 11 | Bone diseases |
| osimertinib | 65 | 14 | Antineoplastics |
| blinatumomab | 64 | 14 | Antineoplastics |
| tofacitinib | 60 | 13 | Immunosuppressants |
| mepolizumab | 59 | 15 | Obstructive airway diseases |
| ipilimumab | 58 | 14 | Antineoplastics |
| zanubrutinib | 58 | 16 | Antineoplastics |
| trastuzumab | 57 | 9 | Antineoplastics |
| guselkumab | 56 | 13 | Immunosuppressants |
| risankizumab | 56 | 14 | Immunosuppressants |
| bimekizumab | 55 | 14 | Immunosuppressants |
| cemiplimab | 55 | 13 | Antineoplastics |
| ravulizumab | 54 | 15 | Immunosuppressants |
| selpercatinib | 53 | 13 | Antineoplastics |
| enzalutamide | 52 | 12 | Endocrine therapy |
| somatropin | 51 | 9 | Pituitary and hypothalamic hormones |
| ribociclib | 50 | 14 | Antineoplastics |
| ruxolitinib | 50 | 12 | Antineoplastics |
| lenvatinib | 49 | 14 | Antineoplastics |
| nintedanib | 49 | 15 | Antineoplastics |
| baricitinib | 48 | 14 | Immunosuppressants |
| tislelizumab | 48 | 12 | Antineoplastics |
| abemaciclib | 47 | 15 | Antineoplastics |
| amivantamab | 47 | 13 | Antineoplastics |
| vedolizumab | 44 | 12 | Immunosuppressants |
| certolizumab pegol | 43 | 11 | Immunosuppressants |
| avelumab | 42 | 13 | Antineoplastics |
| niraparib | 42 | 15 | Antineoplastics |
| ranibizumab | 41 | 10 | Ophthalmologicals |
| dostarlimab | 39 | 14 | Antineoplastics |
| dabrafenib | 38 | 14 | Antineoplastics |
| darolutamide | 38 | 15 | Endocrine therapy |
| isatuximab | 38 | 12 | Antineoplastics |
| alectinib | 37 | 15 | Antineoplastics |
| obinutuzumab | 37 | 12 | Antineoplastics |
| tisagenlecleucel | 37 | 12 | Antineoplastics |
| cannabidiol | 35 | 12 | Antiepileptics |
| crizotinib | 35 | 12 | Antineoplastics |
| emicizumab | 35 | 12 | Antihemorrhagics |
| abatacept | 34 | 10 | Immunosuppressants |
| axicabtagene ciloleucel | 34 | 12 | Antineoplastics |
| burosumab | 34 | 13 | Bone diseases |
| esketamine | 33 | 13 | Psychoanaleptics |
| natalizumab | 33 | 12 | Immunosuppressants |
| pegcetacoplan | 33 | 16 | Ophthalmologicals |
| hydrocortisone | 32 | 10 | Systemic corticosteroids |
| pertuzumab | 32 | 13 | Antineoplastics |
| benralizumab | 31 | 15 | Obstructive airway diseases |
| canakinumab | 31 | 10 | Immunosuppressants |
| ramucirumab | 31 | 9 | Antineoplastics |
| sacituzumab govitecan | 31 | 15 | Antineoplastics |
| avapritinib | 30 | 11 | Antineoplastics |
| entrectinib | 30 | 13 | Antineoplastics |
| fingolimod | 30 | 12 | Immunosuppressants |
| idelalisib | 30 | 8 | Antineoplastics |
| regorafenib | 30 | 12 | Antineoplastics |
| larotrectinib | 29 | 14 | Antineoplastics |
| palbociclib | 29 | 13 | Antineoplastics |
| apalutamide | 28 | 12 | Endocrine therapy |
| apremilast | 28 | 10 | Immunosuppressants |
| belimumab | 28 | 12 | Immunosuppressants |
| encorafenib | 28 | 12 | Antineoplastics |
| letermovir | 28 | 14 | Antivirals |
| tafamidis | 28 | 16 | Other nervous system |
| abiraterone | 27 | 10 | Endocrine therapy |
| enfortumab vedotin | 27 | 13 | Antineoplastics |
| lisocabtagene maraleucel | 27 | 11 | Antineoplastics |
| vutrisiran | 27 | 15 | Other nervous system |
| fenfluramine | 26 | 14 | Antiepileptics |
| filgotinib | 26 | 13 | Immunosuppressants |
| glofitamab | 26 | 13 | Antineoplastics |
| lorlatinib | 26 | 12 | Antineoplastics |
| azacitidine | 25 | 11 | Antineoplastics |
| brigatinib | 25 | 14 | Antineoplastics |
| cabotegravir | 25 | 10 | Antivirals |
| ivacaftor / lumacaftor | 25 | 11 | Other respiratory |
| sirolimus | 25 | 8 | Immunosuppressants |
| talazoparib | 25 | 13 | Antineoplastics |
| teduglutide | 25 | 12 | Other alimentary tract and metabolism |
| brolucizumab | 24 | 11 | Ophthalmologicals |
| mirikizumab | 24 | 12 | Immunosuppressants |
| odevixibat | 24 | 13 | Bile and liver therapy |